CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of breast cancer.
  
  LEARNING OBJECTIVES

  • Evaluate published research data to guide the selection and duration of neoadjuvant, adjuvant and extended-adjuvant therapy for patients with HER2-overexpressing localized breast cancer.
  • Implement a long-term clinical plan for the care of patients with metastatic HER2-positive breast cancer, incorporating current and recently approved anti-HER2 therapies.
  • Recognize common and rare side effects associated with novel anti-HER2 agents, and use this information to develop supportive management plans for patients undergoing treatment for HER2-positive breast cancer.
  • Evaluate the results of genomic assays and other patient- and treatment-related factors to personalize adjuvant systemic therapy for newly diagnosed ER-positive breast cancer.
  • Consider available clinical trial findings with CDK4/6 inhibitors for localized ER-positive, HER2-negative breast cancer, and assess the optimal role of these agents as a component of adjuvant treatment.
  • Individualize the selection and sequencing of systemic therapy for patients with ER-positive metastatic breast cancer.
  • Review published data supporting the benefit of chemotherapy in combination with anti-PD-1/PD-L1 antibodies for localized or metastatic triple-negative breast cancer (TNBC), and use this information to make treatment recommendations for patients.
  • Evaluate published research findings guiding the selection and sequencing of available therapeutic agents for patients with PD-L1-negative TNBC or those who experience disease progression on front-line chemoimmunotherapy.
  • Appraise efficacy and safety data with PARP inhibitors for patients with localized and metastatic breast cancer and BRCA1/2 mutations, and consider the diagnostic and therapeutic implications.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Javier Cortés, MD, PhD
  Head, IBCC International Breast Cancer Center
  Barcelona, Spain
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Athenex, BioInvent, Bioasis Technologies Inc, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Cellestia, Clovis Oncology, Daiichi Sankyo Inc, Ellipses Pharma, Erytech Pharma, GEMoaB Monoclonals, Gilead Sciences Inc, GlaxoSmithKline, HiberCell, Leuko Labs Inc, Lilly, Menarini Group, Merck Sharp & Dohme LLC, Polyphor, Reveal Genomics, Roche Laboratories Inc, Seagen Inc, Zymeworks Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Baxalta GmbH, Bayer HealthCare Pharmaceuticals, Eisai Inc, F Hoffmann-La Roche Ltd, Guardant Health, Merck Sharp & Dohme LLC, Pfizer Inc, PIQUR Therapeutics, Puma Biotechnology Inc, Queen Mary University of London, Roche Laboratories Inc, Servier Affaires Medicales, Takeda Pharmaceuticals USA Inc; Honoraria: Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Lilly, Merck Sharp & Dohme LLC, Novartis, Pfizer Inc, Roche Laboratories Inc, Samsung Bioepis; Patents: WO 2014/199294 A, US 2019/ 0338368 A1; Stock: MEDSIR, Nektar, Leuko Labs Inc (stock owned by relative); Travel, Accommodation, Expenses: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, Gilead Sciences Inc, Novartis, Pfizer Inc, Roche Laboratories Inc.
  
  Matthew P Goetz, MD
  Erivan K Haub Family Professor of Cancer Research Honoring Richard F Emslander, MD
  Professor of Oncology and Pharmacology
  Director, Mayo Clinic Breast SPORE
  Co-Leader, Women’s Cancer Program
  Chair, Breast Cancer Research Committee
  Vice Chair, Academic and Community Research United (ACCRU)
  Mayo Clinic
  Rochester, Minnesota
  
  Consulting Agreements (Honoraria to institution): ARC Therapeutics, AstraZeneca Pharmaceuticals LP, Biovica, bioTheranostics Inc, Blueprint Medicines, Eagle Pharmaceuticals, Lilly, Novartis, Pfizer Inc, Sanofi Genzyme, Sermonix Pharmaceuticals; Contracted Research (To Institution): Lilly, Pfizer Inc, Sermonix Pharmaceuticals.
  
  Erika Hamilton, MD
  Director, Breast and Gynecologic Research Program
  Sarah Cannon Research Institute/Tennessee Oncology
  Nashville, Tennessee
  
  Consulting Agreements (Paid to Institution): Arcus Biosciences, Arvinas, AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Boehringer Ingelheim Pharmaceuticals Inc, CytomX Therapeutics, Daiichi Sankyo Inc, Dantari, Deciphera Pharmaceuticals Inc, Eisai Inc, Genentech, a member of the Roche Group, Greenwich LifeSciences Inc, H3 Biomedicine, iTeos Therapeutics, Janssen Biotech Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Novartis, Orum Therapeutics, Pfizer Inc, Puma Biotechnology Inc, Relay Therapeutics, Seagen Inc, Silverback Therapeutics; Contracted Research (Paid to Institution): AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, ADC Therapeutics, Akesobio Australia Pty Ltd, Amgen Inc, ArQule Inc, Arvinas, AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, Compugen, Curis Inc, CytomX Therapeutics, Daiichi Sankyo Inc, Dana-Farber Cancer Institute, Deciphera Pharmaceuticals Inc, eFFECTOR Therapeutics Inc, Ellipses Pharma, EMD Serono Inc, Fochon Pharmaceuticals Ltd, FUJIFILM Pharmaceuticals USA Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, H3 Biomedicine, Harpoon Therapeutics, Hutchison MediPharma, ImmunoGen Inc, Immunomedics Inc, Incyte Corporation, InventisBio, Jacobio Pharmaceuticals Group Co Ltd, Karyopharm Therapeutics, Leap Therapeutics Inc, Lilly, Lycera, MacroGenics Inc, Marker Therapeutics Inc, Merck, Mersana Therapeutics Inc, Merus BV, Molecular Templates, Myriad Genetic Laboratories Inc, Novartis, NuCana, Olema Oncology, OncoMed Pharmaceuticals Inc, Onconova Therapeutics Inc, ORIC Pharmaceuticals Inc, Orinove Inc, Pfizer Inc, PharmaMar, Pieris Pharmaceuticals Inc, Pionyr Immunotherapeutics, Plexxikon Inc, Puma Biotechnology Inc, Radius Health Inc, Regeneron Pharmaceuticals Inc, Repertoire Immune Medicines, Rgenix, Seagen Inc, Sermonix Pharmaceuticals, Shattuck Labs, Silverback Therapeutics, Stemcentrx, Sutro Biopharma, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, Transcenta Holding Ltd, Treadwell Therapeutics, Verastem Inc, Vincerx Pharma, Zenith Epigenetics, Zymeworks Inc.
  
  Ian E Krop, MD, PhD
  Associate Director, Clinical Research
  Director, Clinical Trials Office
  Chief Clinical Research Officer
  Yale Cancer Center
  New Haven, Connecticut
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, MacroGenics Inc, Seagen Inc, Taiho Oncology Inc; Contracted Research (Clinical Trial Support Paid to Institution): Genentech, a member of the Roche Group, MacroGenics Inc, Pfizer Inc.
  
  Hope S Rugo, MD
  Professor of Medicine
  Director, Breast Oncology and Clinical Trials Education
  University of California, San Francisco
  Helen Diller Family Comprehensive Cancer Center
  San Francisco, California
  
  Consulting Agreement: Samsung Bioepis (limited consulting); Contracted Research: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Immunomedics Inc, Lilly, MacroGenics Inc, Merck, Novartis, OBI Pharma Inc, Odonate Therapeutics, Pfizer Inc, Seagen Inc, Sermonix Pharmaceuticals; Honoraria: Mylan, Puma Biotechnology Inc; Travel: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, MacroGenics Inc, Merck, Mylan, Novartis, Pfizer Inc.
  
  Sara M Tolaney, MD, MPH
  Chief, Division of Breast Oncology
  Associate Director, Susan F Smith Center for Women's Cancers
  Senior Physician
  Dana-Farber Cancer Institute
  Associate Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: 4D Pharma PLC, AstraZeneca Pharmaceuticals LP, Athenex, BeyondSpring Pharmaceuticals Inc, Bristol-Myers Squibb Company, Certara, Chugai Pharmaceutical Co Ltd, CytomX Therapeutics, Daiichi Sankyo Inc, Eisai Inc, Ellipses Pharma, Genentech, a member of the Roche Group, Gilead Sciences Inc, Infinity Pharmaceuticals Inc, Kyowa Kirin Co Ltd, Lilly, Merck, Mersana Therapeutics Inc, NanoString Technologies, Nektar, Novartis, Odonate Therapeutics, OncoPep, OncoSec Medical, OncXerna Therapeutics Inc, Pfizer Inc, Puma Biotechnology Inc, Samsung Bioepis, Sanofi Genzyme, Seagen Inc, Zentalis Pharmaceuticals, Zymeworks Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Cyclacel Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, NanoString Technologies, Nektar, Novartis, Odonate Therapeutics, Pfizer Inc, Sanofi Genzyme, Seagen Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Epizyme Inc, Exact Sciences Corporation, the parent company of GHI, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Exact Sciences, Gilead Sciences Inc, Lilly, Merck, Puma Biotechnology Inc, Sanofi Genzyme, and Seagen Inc.
  
  Release date: June 2022
  Expiration date: June 2023
  
  After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.